Cipla ensures rigorous drug quality through a comprehensive, multi-layered quality management system that governs every single stage of the pharmaceutical manufacturing process, from raw material procurement to final product distribution. The corporation operates state-of-the-art manufacturing facilities globally that are strictly designed to comply with Current Good Manufacturing Practices (cGMP) mandated by elite international regulatory authorities, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). To maintain these uncompromising standards, Cipla employs thousands of quality control analysts and scientists who conduct continuous testing on active pharmaceutical ingredients, excipients, and finished dosage forms using advanced analytical instrumentation to verify purity, potency, and stability. Furthermore, the company routinely undergoes intense facility audits and unannounced regulatory inspections to ensure absolute compliance with global safety protocols, while simultaneously investing heavily in digital automation and data integrity software to prevent human error and secure the pharmaceutical supply chain against contamination or substandard production.